Ipilimumab + nivolumab
Ipilimumab + nivolumab is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
3
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
Clinical Trials (4)
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4